The binding of PD-L1 to PD-1 results in T-cell suppression and inactivation. In cancer, PD-1/PD-L1 signaling serves as a mechanism for tumors to evade an immunologic response, thus promoting cancer progression and survival.1,2
Avelumab is a fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and adaptive immune responses. By retaining a native Fc-region, avelumab is designed to engage the innate immune system and induce antibody-dependent cellular cytotoxicity (ADCC).1,3
Avelumab is thought to selectively bind PD-L1, inhibiting PD-1/PD-L1 interactions and promoting a T-cell mediated antitumor response. Preclinical models also suggest that innate effector function may contribute to antitumor activity.1,4,5
Based on preclinical data in murine models; may not necessarily correlate with clinical outcomes.
Avelumab is being developed and commercialized in a strategic global alliance between EMD Serono and Pfizer Inc.
Please see full Prescribing Information.
Fc, fragment crystallizable; FcγR, receptor for Fc part of IgG; IgG1, immunoglobulin G1; mAb, monoclonal antibody; NK, natural killer; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; TGF-β, transforming growth factor-β; TIGIT, T-cell immunoglobulin and ITIM domain.